Oční forma toxoplazmózy - hledání strategie léčby
[Ocular toxoplasmosis - seeking a strategy for treatment]
Language Czech Country Czech Republic Media print
Document type Journal Article
PubMed
25702053
- MeSH
- Anti-Bacterial Agents administration & dosage therapeutic use MeSH
- Adult MeSH
- Adrenal Cortex Hormones administration & dosage therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Toxoplasmosis, Ocular drug therapy MeSH
- Recurrence MeSH
- Retrospective Studies MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Adrenal Cortex Hormones MeSH
AIM: To compare the effectiveness of treatment for ocular toxoplasmosis with pyrimethamine + clindamycin (or sulfadiazine) + a corticoid (Group 1), or azithromycin or a combination of azithromycin with a corticoid or a corticoid alone (Group 2). To determine the relapse rate depending on the treatment approach. MATERIAL AND METHODS: A total of 25 patients treated for ocular toxoplasmosis over the last five years (2008-2013) were analyzed. Group 1 comprised 16 patients (3 were excluded) and Group 2 consisted of 6 patients. RESULTS: Visual improvement was more rapid in Group 1 (day 10.7) than in Group 2 (significant improvement on day 29.6). There were 5 cases of relapse in Group 1; in 13 cases, no relapse was noted; all patients in Group 2 relapsed (a total of 13 relapses). Twenty-three patients were positive for specific IgG antibodies. CONCLUSION: According to our experiences, pyrimethamine + clindamycin (or sulfadiazine) + a corticoid should be the treatment of choice in patients with ocular toxoplasmosis.
